Media

Risks for UK Biotech (The Times)

Risks for UK Biotech (The Times)

"Funding cuts, a brain drain, skittish drug companies — a post-Brexit cloud hangs over life sciences"

John Rountree, Managing Partner of Novasecta, was recently quoted in the Sunday Times, the UK’s leading Sunday newspaper. In an article entitled “How to Make Our Scientists Very Mad” John offers commentary on the risks of Brexit to early-stage biotech companies, stating that the potential for decreased funding (from Horizon 2020, for example) may reduce the attractiveness of life sciences “hubs” such as London, Cambridge and Oxford. The article goes on to say that diminished research output of academia and biotechs from these hubs, combined with the likely relocation of the European Medicines Agency (EMA), may delay new medicines reaching British patients by two to three years.

Share
Book a Conversation